Tag Archives: drugs

China Investment Firm Seeks Novel Oncology/First-In-Class Therapeutic Drugs and Diagnostics

19 Jul

A biotech incubator sector fund founded in 2015 is headquartered in China with an additional USA office. The firm currently manages two venture funds including an RMB and USD fund. The firm can allocate from $200,000 to $800,000 of equity capital in seed round companies and can make investments ranging from $1 to $10 million in series A companies. The firm looks to tailor its incubator and CRO services to the needs of its partners, helping them to reach key value-added milestones. The firm will consider opportunities based in China and North America, companies within a strong China angle involvement is their sweet spot. The firm is actively seeking in-licensing opportunities and plans to make 6-8 investments next year but is flexible.

The firm focuses mostly on therapeutics, while the firm is also open to Diagnostics. The firm can utilize its CRO services to advance portfolio company’s products into or through clinical trials. The firm is currently most interested in oncology-related small molecule drugs and first-in-class drugs. The firm is opportunistic in terms of subsector and indication and is willing to consider companies targeting orphan indications. For therapeutics, the firm is looking to invest in pre-clinical stage. For diagnostics, the firm will consider companies from in-development to clinical stages. The firm will not invest in Medical Devices or Healthcare IT companies.

The firm looks to act as a lead investor in seed round investments and can participate as either lead or co-investor in series A investments. The firm is looking for companies with skilled and experienced management teams. The firm prefers to support companies that own exclusive IP protection with renowned universities or research institutions. The firm also prefers to work with companies that have a technical expert and experienced in clinical trials.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: Korean Pharmaceutical Company Seeks In-Licensing Opportunities at All Stages, with Strong Interest in NCEs and First-In-Class Drugs

26 Apr

A large pharmaceutical company headquartered in Seoul, South Korea specializes in developing, manufacturing, and supplying pharmaceutical products that contribute to the health and happiness of humankind, including resistant bacteria, malignant tumors, Alzheimer’s disease, obesity, and aging. The company’s strengths lie in the development of raw vitamins, probiotics, and antimicrobials, as well as strong market share in clinics and hospitals, and robust experience in marketing, promotion, distribution, and R&D.

The company works with global pharmaceutical companies to manufacture original prescription drugs and utilizes is internal synthesis capacity to manufacture a wide variety of generic prescription drugs. The company is currently expanding into functional health food, medical device, cosmetic, and beverage industries and evolving into a total healthcare company of global proportions. The company is actively seeking early to late-stage drugs globally for in-licensing, co-development, or acquisition.

The company is seeking early to late-stage therapeutic drugs with strong interests in these following indications: oncology, CNS, gastrointestinal (GI), autoimmune, endocrine and metabolic diseases. The company is most interested in NCEs and first/best-in-class MOA.

The company seeks to partner with teams with strong scientific expertise who are working on novel technologies, and is flexible in terms of distribution rights.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Life Science Investor Mandate 3: Venture Arm Focuses on Companies Developing New Drugs, Devices

31 Oct

The corporate venture arm of a larger foundation based in Europe has approximately $35 billion in AUM, provides (equity only) seed and venture capital to development stage companies, and also takes significant ownership positions in well-established companies within life science and biotechnology.

The firm will invest at any stage of development – seed, venture, and growth. They also make late-stage investments in public/private companies with a positive cash flow, and can allocate up to $40M or more depending on specific cases, but generally allocate between $5M and $20M. The firm seeks companies that are based in North America and Europe, but has no current mandate for the number of allocations it plans to make.

The venture arm is opportunistic in the life sciences space. Specifically, they focus on companies that specialize in the development of new drugs, new procedures for diagnosis and control of diseases, development of medical devices and instruments, and industrial biotechnology. They are very opportunistic in terms of subsectors and indications.

Currently, this particular firm is active in companies developing therapeutics and diagnostics targeting cardiovascular diseases, infectious diseases, immune disorders, diseases of the nervous system, mental and behavioral disorders, and cancer. Additionally, they have invested in companies developing therapeutics based on small molecules and antibodies. The firm has also made venture investments in companies developing medical technology in the area of reusable instruments, wound care, single use devices, therapeutic radiation devices, and active implantable devices.

 

%d bloggers like this: